Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beta Bionics (BBNX) Research & Development (2024 - 2025)

Beta Bionics (BBNX) has disclosed Research & Development for 2 consecutive years, with $10.1 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 9.95% to $10.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $34.8 million through Dec 2025, up 32.86% year-over-year, with the annual reading at $34.8 million for FY2025, 32.86% up from the prior year.
  • Research & Development hit $10.1 million in Q4 2025 for Beta Bionics, up from $8.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $10.1 million in Q4 2025 to a low of $5.1 million in Q3 2024.